Keywords: morphotek, gets, protocol, appro, ph, ii, sites
Morphotek gets protocol appro for Ph II sites
Article | 28 May 2007
Morphotek, a US subsidiary of Japan's Eisai, has received approval of protocol by the Paul-Ehrlich-Institute, Germany's regulatory authority charged with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
